Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer

Core Insights - Pasithea Therapeutics has received a recommendation from the external Safety Review Committee to escalate the trial to the next dose level of 15mg capsule due to the absence of dose-limiting toxicities and rashes observed in the initial patients [1][2] - The Phase 1 clinical trial is designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of PAS-004 in patients with advanced solid tumors driven by the MAPK pathway [2][3] - PAS-004 is differentiated from first-generation MEK inhibitors by its potential for once-daily dosing and a long half-life of approximately 70 hours, which may reduce toxicity risks [3] Company Overview - Pasithea Therapeutics is focused on developing innovative treatments for central nervous system disorders and RASopathies, with a team experienced in neuroscience, translational medicine, and drug development [4]